Tumors promote altered maturation and early apoptosis of monocyte- derived dendritic cells

Journal of Immunology

Volumn 164, Issue 3, 2000, Pages 1269-1276

  Kiertscher, Sylvia M ^a,b   Luo, Jie ^a   Dubinett, Steven M ^a,b,c   Roth, Michael D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL;

EID: 0034141907     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.3.1269     Document Type: Article

References (50)

1. Chouaib, S., C. Asselin-Paturel, F. Mami-Chouaib, A. Caignard, and J. Y. Blay. 1997. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol. Today 18:493.
2. Wojtowiez-Praga, S. 1997. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J. Immunother. 20:165.
3. Antonia, S. J., M. Extermann, and R. A. Flavell. 1998. Immunologic nonresponsiveness to tumors. Crit. Rev. Oncog. 9:35.
4. Botti, C., E. Seregni, L. Ferrari, A. Martinetti, and E. Bombardieri. 1998. Immunosuppressive factors: role in cancer development and progression. Int. J. Biol. Markers 13:51.
5. Hart, D. N. 1997. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90:3245.
6. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.
7. Schuler, G., and R. M. Steinman. 1997. Dendritic cells as adjuvants for immunemediated resistance to tumors. J. Exp. Med 186:1183.
8. Gabrilovich, D. I., I. F. Ciernik, and D. P. Carbone. 1996. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol. 170:101.
9. Chaux, P., N. Favre, M. Martin, and F. Martin. 1997. Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats. Int. J. Cancer 72:619.
10. Gabrilovich, D. I., J. Corak, I. F. Ciernik, D. Kavanaugh, and D. P. Carbone. 1997. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin. Cancer Res. 3:483.
11. Radmayr, C., G. Bock, A. Hobisch, H. Klocker, G. Bartsch, and M. Thurnher. 1995. Dendritic antigen-presenting cells from the peripheral blood of renal cell carcinoma patients. Int. J. Cancer 63:627.
12. Troy, A. J. K. L. Summers, P. J. Davidson, C. H. Atkinson, and D. N. Hart. 1998. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin. Cancer Res. 4:585.
13. Enk, A. H., H. Jonuleil, S. Jaloga, and J. Knop. 1997. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int. J. Cancer 73:3096.
14. Gabrilovich, D. I., H. L. Chen, K. R. Girgis, H. T. Cunningham, G. M. Meny, S. Nadaf, D. Kavanaugh, and D. P. Carbone. 1996. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells, Nat. Med. 2:1096.
15. + progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92:4778.
16. Oyama, T., S. Ran, T. Ishida, S. Nadaf, L. Kerr, D. P. Carbone, and D. I. Gabrilovich. 1998. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in hemopoietic progenitor cells. J. Immunol. 160:1224.
17. + leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J. Leukocyte Biol. 59:208.
18. + dendritic cells. Proc. Natl. Acad. Sci. USA 93: 2588.
19. Romani, N., S. Gruner, D. Brang, E. Kampgen, A. Lenz, B. Trockenbacher, G. Konwalinka, P. O. Fritsch, R. M. Steinman, and G. Schuler 1994. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180:83.
20. Sallusto, F., M. Cella, C. Danieli, and A. Lanzavecchia. 1995. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: down-regulation by cytokines and bacterial products, J. Exp. Med. 182:389.
21. Kalinski, P., C. M. Hilkens, A. Snijders, F. G. Snijdewint, and M. L. Kapsenberg. 1997. IL-12-deficient dendritic cells, generated in the presence of proslaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J. Immunol. 159:28.
22. De Smedt, T., M. Van Mechelen, G. De Becker, J. Urbain, O. Leo, and M. Moser. 1997. Effect of interleukin-10 on dendritic cell maturation and function. Eur. J. Immunol. 27:1229.
23. Buelens, C., V. Verhassell, D. De Groote, K. Thielemans, M. Goldman, and F. Willems. 1997. Human dendritic cell responses to lipopolysaccharide and CD40 ligation are differentially regulated by interleukin-10. Eur. J. Immunol. 27:1848.
24. Allavena, P., L. Piemonti, D. Longoni, S. Bernasconi, A. Stoppacciaro, L. Ruco, and A. Mantovani. I99S. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur. J. Immunol. 28: 359.
25. Huang, M., J. Wang, P. Lee, S. Sharma, J. T. Mao, H. Meissner, K. Uyemura, R. Modlin, J. Wollman, and S. M. Dubinett. 1995. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res. 55:3847.
26. Koyama, S., E. Sato, H. Nomura, K. Kubo, M. Miura, T. Yamashita, S. Nagai, and T. Izumi. 1999. Monocyte chemotactic factors released from lype II pneumocyte-like cells in response to TNF-α and IL-1α. Eur. Respir. J. 13:820.
27. Amirkhosravi, A., T. Meyer, G. Warnes, M. Amaya, Z. Malik, J. P. Biggerstaff, F.A. Siddiqui, P. Sherman, and J. L. Francis. 1998. Pentoxifylline inhibits hypoxia-induced up-regulation of tumor cell tissue factor and vascular endothelial growth factor. Thromb. Haemostasis 80:598.
28. Rescigno, M., F. Granucci, S. Citterio, M. Foti, and P. Ricciardi-Castagnoli. 1999. Coordinated events during bacteria-induced DC maturation. Immunol. Today 20:200.
29. Pettit, A. R., C. Quinn, K. P. MacDonald, L. L. Cavanagh, G. Thomas, W. Townsend, M. Handel, and R. Thomas. 1997. Nuclear localization of Re1B is associated with effective antigen-presenting cell function. J. Immunol. 159:3681.
30. Cella, M., F. Sallusto, and A. Lanzavecchia. 1997. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 9:10.
31. Mackey, M. F., J. R. Gunn, C. Maliszewsky, H. Kikutani, R. J. Noelle, and R. J. Barth, Jr. 1998. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J. Immunol. 161:2094.
32. Caux, C., C. Massacrier, B. Vanbervliet, B. Dubois, C. Van Kooten, I. Durand. and J. Banchereau. 1994. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 180:1263.
33. Morse, M. A., H. K. Lyerly, E. Gilboa, E. Thomas, and S. K. Nair. 1998. Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. Cancer Res. 58:2965.
34. Reddy, A., M. Sapp, M. Feldman, M. Subklewe, and N. Bhardwaj. 1997. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. Blood 90:3640.
35. Romani, N., D. Reider, M. Heuer, S. Ebner, E. Kampgen, B. Eibl, D. Niederwieser, and G. Schuler. 1996. Generation of mature dendritic cells from human blood: an improved method with special regard to clinical applicability. J. Immunol. Methods 196:137.
36. Schwarz, A., S. Grabbe, K. Grosse-Heitmeyer, B. Roters, H. Riemann, T. A. Luger, G. Trinchieri, and T. Schwarz. 1998. Ultraviolet light-induced immune tolerance is mediated via the Fas/Fas-ligand system. J. Immunol. 160:4262.
37. Esche, C., A. Gambotto, Y. Satoh, V. Gerein, P. D. Robbins, S. C. Watkins, M. T. Lotze, and M. R. Shurin. 1999. CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth. Eur. J. Immunol. 29:2148.
38. Zeid, N. A., and H. K. Muller. 1993. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 25: 338.
39. Hilkens, C. M., P. Kalinski, M. de Boer, and M. L. Kapsenberg. 1997. Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood 90:1920.
40. Grohmann, U., R. Bianchi, E. Ayroldi, M. L. Belladonna, D. Surace, M. C. Fioretti, and P. Puccetti. 1997. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J. Immunol. 158:3593.
41. Huang, M., M. Stolina, S. Sharma, J. T. Mao, L. Zhu, P. W. Miller, J. Wollman, H. Herschman, and S. M. Dubinett. 1998. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res. 58:1208.
42. + T cells resulting in a failure to lyse tumor cells. Blood 93:1634.
43. Steinbrink, K., M. Wolfl, H. Jonuleit, J. Knop, and A. H. Enk. 1997. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 159:4772.
44. Akbar, A. N., and M. Salmon. 1997. Cellular environments and apoptosis: tissue microenvironments control activated T-cell death. Immunol. Today 18:72.
45. Wong, B. R., R. Josien, S. Y. Lee, B. Sauter, H. L. Li, R. M. Steinman, and Y. Choi. 1997. TRANCE (tumor necrosis factor (TNF)-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186:2075.
46. Koppi, T. A., T. Tough-Bement, D. M. Lewinsohn, D. H. Lynch, and M. R. Alderson. 1997. CD40 ligand inhibits Fas/CD95-mediated apoptosis of human blood-derived dendritic cells. Eur. J. Immunol. 27:3161.
47. De Smedt, T., B. Pajak, G. G. Klaus, R. J. Noelle, J. Urbain, O. Leo, and M. Moser. 1998. Antigen-specific T lymphocytes regulate lipopolysaccharide-induced apoptosis of dendritic cells in vivo. J. Immunol. 161:4476.
48. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med 4:328.
49. Tjoa, B. A., S. J. Simmons, V. A. Bowes, H. Ragde, M. Rogers, A. Elgamal, G. M. Kenny, O. E. Cobb, R. C. Ireton, M. J. Troychak. et al. 1998. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36:39.
50. Lotze, M. T., B. Hellerstedt, L. Stolinski, T. Tueting, C. Wilson, D. Kinzler, H. Vu, J. T. Rubin, W. Slorkus, and H. Tahara. 1997. The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy. Cancer J. Sci. Am. 3(Suppl. 1):S109.